Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients

Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients

Abstract To report outcomes and risk factors of ultrahypofractionated (UHF) radiotherapy for Japanese prostate cancer patients. This multi-institutional retrospective analysis comprised 259 patients with localized prostate cancer from 6 hospitals. A total dose of 35–36 Gy in 4–5 fractions was prescr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hiromichi Ishiyama, Hideyasu Tsumura, Hisato Nagano, Motoi Watanabe, Eiichi Mizuno, Masashi Taka, Hiroaki Kobayashi, Takahisa Eriguchi, Hajime Imada, Koji Inaba, Katsumasa Nakamura
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/677e0ef19ae74f80ac3d0cd39cbf41cc
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:677e0ef19ae74f80ac3d0cd39cbf41cc
record_format dspace
spelling oai:doaj.org-article:677e0ef19ae74f80ac3d0cd39cbf41cc2021-12-02T18:02:53ZMulti-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients10.1038/s41598-021-92307-82045-2322https://doaj.org/article/677e0ef19ae74f80ac3d0cd39cbf41cc2021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92307-8https://doaj.org/toc/2045-2322Abstract To report outcomes and risk factors of ultrahypofractionated (UHF) radiotherapy for Japanese prostate cancer patients. This multi-institutional retrospective analysis comprised 259 patients with localized prostate cancer from 6 hospitals. A total dose of 35–36 Gy in 4–5 fractions was prescribed for sequential or alternate-day administration. Biochemical failure was defined according to the Phoenix ASTRO consensus. Toxicities were assessed using National Cancer Institute Common Toxicity Criteria version 4. Tumor control and toxicity rates were analyzed by competing risk frames. Median follow-up duration was 32 months (range 22–97 months). 2- and 3-year biochemical control rates were 97.7% and 96.4%, respectively. Initial prostate-specific antigen (p < 0.01) and neoadjuvant androgen deprivation therapy (p < 0.05) were identified as risk factors for biochemical recurrence. 2- and 3-year cumulative ≥ Grade 2 late genitourinary (GU) toxicities were 5.8% and 7.4%, respectively. Corresponding rates of gastrointestinal (GI) toxicities were 3.9% and 4.5%, respectively. Grade 3 rates were lower than 1% for both GU and GI toxicities. No grade 4 or higher toxicities were encountered. Biologically effective dose was identified as a risk factor for ≥ Grade 2 late GU and GI toxicities (p < 0.05). UHF radiotherapy offered effective, safe treatment for Japanese prostate cancer with short-term follow-up. Our result suggest higher prescribed doses are related to higher toxicity rates.Hiromichi IshiyamaHideyasu TsumuraHisato NaganoMotoi WatanabeEiichi MizunoMasashi TakaHiroaki KobayashiTakahisa EriguchiHajime ImadaKoji InabaKatsumasa NakamuraNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Hiromichi Ishiyama
Hideyasu Tsumura
Hisato Nagano
Motoi Watanabe
Eiichi Mizuno
Masashi Taka
Hiroaki Kobayashi
Takahisa Eriguchi
Hajime Imada
Koji Inaba
Katsumasa Nakamura
Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients
description Abstract To report outcomes and risk factors of ultrahypofractionated (UHF) radiotherapy for Japanese prostate cancer patients. This multi-institutional retrospective analysis comprised 259 patients with localized prostate cancer from 6 hospitals. A total dose of 35–36 Gy in 4–5 fractions was prescribed for sequential or alternate-day administration. Biochemical failure was defined according to the Phoenix ASTRO consensus. Toxicities were assessed using National Cancer Institute Common Toxicity Criteria version 4. Tumor control and toxicity rates were analyzed by competing risk frames. Median follow-up duration was 32 months (range 22–97 months). 2- and 3-year biochemical control rates were 97.7% and 96.4%, respectively. Initial prostate-specific antigen (p < 0.01) and neoadjuvant androgen deprivation therapy (p < 0.05) were identified as risk factors for biochemical recurrence. 2- and 3-year cumulative ≥ Grade 2 late genitourinary (GU) toxicities were 5.8% and 7.4%, respectively. Corresponding rates of gastrointestinal (GI) toxicities were 3.9% and 4.5%, respectively. Grade 3 rates were lower than 1% for both GU and GI toxicities. No grade 4 or higher toxicities were encountered. Biologically effective dose was identified as a risk factor for ≥ Grade 2 late GU and GI toxicities (p < 0.05). UHF radiotherapy offered effective, safe treatment for Japanese prostate cancer with short-term follow-up. Our result suggest higher prescribed doses are related to higher toxicity rates.
format article
author Hiromichi Ishiyama
Hideyasu Tsumura
Hisato Nagano
Motoi Watanabe
Eiichi Mizuno
Masashi Taka
Hiroaki Kobayashi
Takahisa Eriguchi
Hajime Imada
Koji Inaba
Katsumasa Nakamura
author_facet Hiromichi Ishiyama
Hideyasu Tsumura
Hisato Nagano
Motoi Watanabe
Eiichi Mizuno
Masashi Taka
Hiroaki Kobayashi
Takahisa Eriguchi
Hajime Imada
Koji Inaba
Katsumasa Nakamura
author_sort Hiromichi Ishiyama
title Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients
title_short Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients
title_full Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients
title_fullStr Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients
title_full_unstemmed Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients
title_sort multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for japanese prostate cancer patients
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/677e0ef19ae74f80ac3d0cd39cbf41cc
work_keys_str_mv AT hiromichiishiyama multiinstitutionalretrospectiveanalysisofultrahypofractionatedradiotherapyforjapaneseprostatecancerpatients
AT hideyasutsumura multiinstitutionalretrospectiveanalysisofultrahypofractionatedradiotherapyforjapaneseprostatecancerpatients
AT hisatonagano multiinstitutionalretrospectiveanalysisofultrahypofractionatedradiotherapyforjapaneseprostatecancerpatients
AT motoiwatanabe multiinstitutionalretrospectiveanalysisofultrahypofractionatedradiotherapyforjapaneseprostatecancerpatients
AT eiichimizuno multiinstitutionalretrospectiveanalysisofultrahypofractionatedradiotherapyforjapaneseprostatecancerpatients
AT masashitaka multiinstitutionalretrospectiveanalysisofultrahypofractionatedradiotherapyforjapaneseprostatecancerpatients
AT hiroakikobayashi multiinstitutionalretrospectiveanalysisofultrahypofractionatedradiotherapyforjapaneseprostatecancerpatients
AT takahisaeriguchi multiinstitutionalretrospectiveanalysisofultrahypofractionatedradiotherapyforjapaneseprostatecancerpatients
AT hajimeimada multiinstitutionalretrospectiveanalysisofultrahypofractionatedradiotherapyforjapaneseprostatecancerpatients
AT kojiinaba multiinstitutionalretrospectiveanalysisofultrahypofractionatedradiotherapyforjapaneseprostatecancerpatients
AT katsumasanakamura multiinstitutionalretrospectiveanalysisofultrahypofractionatedradiotherapyforjapaneseprostatecancerpatients
_version_ 1718378809780076544

Ejemplares similares